ENBIO Q1 Net Profit 2.21B Won, Exceeding Full-Year 2025 Net Profit of 1.01B Won

Q1 2026 revenue 14.14B won (↑2.2% YoY), operating profit 3.13B won (significant improvement vs FY2025 operating profit of 0.92B won)
Quarterly net profit 2.21B won, basic EPS 203 won (vs FY2025 net profit 1.01B won, EPS 93 won)
Total assets 74.15B won, liabilities 29.59B won, equity 44.56B won, retained earnings -8.48B won (deficit reduced)
Borrowings: short-term 9.28B won, long-term 9.14B won; collateral provided assets 21.89B won and CEO guarantees
R&D expenses 0.23B won (1.63% of sales), 13 registered patents, 182 product registrations
Agenda items on amendments to articles of incorporation and director compensation limit were rejected at the 29th AGM